source
- MPM BioImpact adds three China-origin drug programs to K2 Therapeutics portfolioMPM BioImpact, a biotech investment firm, is intensifying its "best of both worlds" approach by bringing drug candidates that originated in China to a broader market. Over the past year its portfo…
- FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by AmgenThe U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…